Vivani Medical (VANI) 10-Q 7 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document And Entity Information
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	1,266,806
Document Type	10-Q
Trading Symbol	EYES
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		56,794,477
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 763	$ 539
Money market funds	17,366	10,336
Accounts receivable, net	926	274
Inventories, net	3,052	3,416
Prepaid expenses and other current assets	702	717
Total current assets	22,809	15,282
Property and equipment, net	1,414	1,489
Deposits and other assets	44	39
Total assets	24,267	16,810
Current liabilities:
Accounts payable	558	1,156
Accrued expenses	2,304	2,088
Accrued compensation expense	1,823	1,600
Accrued clinical trial expenses	632	629
Deferred revenue	147	85
Deferred grant revenue		104
Total current liabilities	5,464	5,662
Commitments and contingencies
Stockholders' equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 200,000 shares authorized; shares issued and outstanding: 56,794 and 42,701 at June 30, 2017 and December 31, 2016, respectively	200,867	186,769
Common stock to be issued	21	153
Additional paid-in capital	38,654	30,697
Notes receivable to finance stock option exercises	(1)	(2)
Accumulated other comprehensive loss	(486)	(608)
Accumulated deficit	(220,252)	(205,861)
Total stockholders' equity	18,803	11,148
Total liabilities and stockholders' equity	$ 24,267	$ 16,810

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, authorized	10,000	10,000
Preferred stock, outstanding	0	0
Common stock, no par value (in dollars per share)
Common stock, authorized	200,000	200,000
Common stock, issued	56,794	42,701
Common stock, outstanding	56,794	42,701

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net sales	$ 2,236	$ 1,037	$ 3,245	$ 2,090
Cost of sales	1,127	3,241	2,254	4,153
Gross profit (loss)	1,109	(2,204)	991	(2,063)
Operating expenses:
Research and development, net of grants	1,949	916	3,796	1,678
Clinical and regulatory	684	568	1,298	1,346
Selling and marketing	2,447	2,199	4,682	4,211
General and administrative	2,901	2,620	5,642	5,030
Total operating expenses	7,981	6,303	15,418	12,265
Loss from operations	(6,872)	(8,507)	(14,427)	(14,328)
Interest income	29	3	36	8
Net loss	$ (6,843)	$ (8,504)	$ (14,391)	$ (14,320)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.12)	$ (0.23)	$ (0.28)	$ (0.39)
Weighted average common shares outstanding - basic and diluted (in shares)	56,513	37,540	51,380	36,756

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,843)	$ (8,504)	$ (14,391)	$ (14,320)
Other comprehensive income (loss):
Foreign currency translation adjustments	92	(30)	122	23
Comprehensive loss	$ (6,751)	$ (8,534)	$ (14,269)	$ (14,297)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Notes Receivable for Stock Option Exercises [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance beginning at Dec. 31, 2015	$ 166,049	$ 205	$ 27,277	$ (5)	$ (581)	$ (172,682)	$ 20,263
Balance beginning (in shares) at Dec. 31, 2015	35,942	33
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance common stock in connection with rights offering, net of expenses	$ 19,430						19,430
Issuance common stock in connection with rights offering, net of expenses (in shares)	5,978
Issuance of common stock in connection with Employee Stock Purchase Plan	$ 337						337
Issuance of common stock in connection with Employee Stock Purchase Plan (in shares)	102
Fair value of stock options issued for services in connection with rights offering			53				53
Exercise of stock options	$ 478			2			480
Exercise of stock options (in shares)	95
Stock-based compensation expense			1,682				1,682
Stock issued or issuable for professional services	$ 324	$ (183)					141
Stock issued or issuable for professional services (in shares)	82	(27)
Comprehensive loss
Net loss						(14,320)	(14,320)
Foreign currency translation adjustment					23		23
Comprehensive loss					23	(14,320)	(14,297)
Balance ending at Jun. 30, 2016	$ 186,618	$ 22	29,012	(3)	(558)	(187,002)	28,089
Balance ending (in shares) at Jun. 30, 2016	42,199	6
Balance beginning at Dec. 31, 2016	$ 186,769	$ 153	30,697	(2)	(608)	(205,861)	$ 11,148
Balance beginning (in shares) at Dec. 31, 2016	42,701	77					42,701
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of common stock and warrants in connection with rights offering, net of offering costs	$ 13,647		6,021				$ 19,668
Issuance of shares of common stock and warrants in connection with rights offering, net of offering costs (in shares)	13,653
Issuance of common stock in connection with Employee Stock Purchase Plan	$ 189						189
Issuance of common stock in connection with Employee Stock Purchase Plan (in shares)	193
Fair value of stock options issued for services in connection with rights offering			20				20
Common stock issued or issuable for services	$ 262	$ (132)					$ 130
Common stock issued or issuable for services (in shares)	223	(59)
Exercise of stock options (in shares)
Issuance of RSUs
Issuance of RSUs (in shares)	24
Stock-based compensation expense			1,916				1,916
Repayment of notes receivable for stock option exercises				1			1
Comprehensive loss
Net loss						(14,391)	(14,391)
Foreign currency translation adjustment					122		122
Comprehensive loss					122	(14,391)	(14,269)
Balance ending at Jun. 30, 2017	$ 200,867	$ 21	$ 38,654	$ (1)	$ (486)	$ (220,252)	$ 18,803
Balance ending (in shares) at Jun. 30, 2017	56,794	18					56,794

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (14,391)	$ (14,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	229	203
Stock-based compensation	1,916	1,682
Bad debt (recovery) expense	(36)	191
Excess inventory (recovery) reserve	(1,456)	1,523
Common stock issuable for services	130	141
Changes in operating assets and liabilities:
Accounts receivable	(704)	627
Inventories	1,887	(659)
Prepaid expenses and other assets	13	469
Accounts payable	(528)	(39)
Accrued expenses	206	(313)
Accrued compensation expenses	224	(394)
Accrued clinical trial expenses	3	(65)
Deferred revenue	56	(61)
Deferred grant revenue	(104)	(1,092)
Net cash used in operating activities	(12,555)	(12,107)
Cash flows from investing activities:
Purchases of property and equipment	(151)	(295)
Investment in money market funds	(7,022)	(7,968)
Net cash used in investing activities	(7,173)	(8,263)
Cash flows from financing activities:
Net proceeds from rights offering	19,688	19,483
Proceeds from repayment of note receivable	1
Proceeds from exercise of options and employee stock plan purchases	189	816
Net cash provided by financing activities	19,878	20,299
Effect of exchange rate changes on cash	74	16
Cash:
Net increase (decrease)	224	(55)
Balance at beginning of period	539	239
Balance at end of period	763	184
Non-cash financing and investing activities:
Fair value of stock options issued for services rendered in connection with rights offering	$ 20	$ 53

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight” or “the Company”), formerly Second Sight LLC, was founded in 1998 as a limited liability company and was subsequently incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa. In 2007, Second Sight formed Second Sight (Switzerland) Sarl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe, the Middle East and Asia. As the laws of Switzerland require at least two corporate stockholders, Second Sight (Switzerland) Sarl is 99.5% owned directly by the Company and 0.5% is owned by an executive of Second Sight, who is acting as a nominee of the Company. Accordingly, Second Sight (Switzerland) Sarl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented. Since its inception, the Company has generated limited revenues from the sale of products and has financed its operations primarily through the issuance of common stock, convertible debt (which has been converted into common stock), and grants primarily from government agencies. On March 6, 2017, the Company successfully completed a registered Rights Offering to existing stockholders raising net proceeds of approximately $19.7 million in which it sold 13.7 million Units at $1.47 per Unit, which was the closing price of the Company’s common stock on that date. Each Unit consisted of a share of the Company’s common stock and a warrant to purchase an additional share of the Company’s stock for $1.47. The warrants have a five-year life and trade on Nasdaq under the symbol EYESW. At the Company’s discretion, the warrants are redeemable on 30 days’ notice (i) at any time 24 months after the date of issuance, (ii) if the shares of its common stock are trading at 200% or higher than the Subscription Price for 15 consecutive trading days and (iii) if all of the independent directors vote in favor of redeeming the warrants. Holders may be able to sell or exercise warrants prior to any announced redemption date and the Company will redeem outstanding warrants not exercised by the announced redemption date for a nominal amount of $0.01 per Warrant. The Company deemed it appropriate not to record the liability for this warrant redemption amount as the probability of any redemptions was deemed remote based upon its terms. For purposes of recording this transaction, the Company allocated the proceeds from the offering between the common stock and warrants issued based on their relative fair values on the date of issuance. The fair value used for the common stock was the closing price of the stock of $1.47 on March 6, 2017. The fair value used for the warrants was their Black-Scholes value of $0.64 per warrant, calculated as of March 6, 2017. Accordingly, the relative fair value assigned to the common stock was $1.02 per share and the relative fair value assigned to the warrants was $0.45 per warrant. The Company is using these proceeds to invest in its business to expand sales and marketing efforts, enhance current products, gain regulatory approvals for additional indications, and continue research and development into next generation technology. The Company evaluated the financial impact of FASB ASC 260, “Earnings per Share,” which states, among other things, that if a rights issue is offered to all existing stockholders at an exercise price that is less than the fair value of the stock, then the weighted average shares outstanding and basic and diluted earnings per share shall be adjusted retroactively to reflect the bonus element of the rights offering for all periods presented. The Company determined that the application of this specific provision of ASC 260 was immaterial to previously issued financial statements and, therefore, did not retroactively adjust previously reported weighted average shares outstanding and basic and diluted earnings per share. The Company’s financial statements have been presented on the basis that its business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on its operating capital resources and uncertain demand for its products. The Company has incurred recurring operating losses and negative operating cash flows since inception, and expects to continue to incur operating losses and negative operating cash flows for at least the next several years as a result of which, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s 2016 consolidated financial statements, has also raised substantial doubt about the Company’s ability to continue as a going concern. The Company believes that it has sufficient funds to last into the second quarter of 2018. To continue business operations beyond that point, the Company will need to raise additional debt and/or equity capital. However, there can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all so as to be able to continue operating its business at current levels past the second quarter of 2018. If cash resources become insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trails, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to its products, or to discontinue its operations entirely.

Basis of Presentation, Signific

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2016 has been derived from the Company’s audited consolidated financial statements. In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods. Significant Accounting Policies The Company’s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2016. Net Operating Loss Carryforward As of December 31, 2016 pursuant to an analysis done under Section 382, Limitations on Net Operating Losses, of the Internal Revenue Code of 1986, as amended, the Company had $142.3 million and $93.8 million of federal and state operating loss carryforwards, respectively, with which to offset any future taxable income. The federal and state net operating loss carryforwards will begin to expire at various dates from 2016 through 2036. If these loss carryforwards are unavailable for use in future periods, the Company’s results of operations and financial position may be adversely affected. The Company experienced an “ownership change” within the meaning of Section 382(g) of the Internal Revenue Code of 1986, as amended, during the second quarter of 2017. The ownership change will subject the Company’s net operating loss carryforwards to an annual limitation, which will significantly restrict the Company’s ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of the Company’s stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. The Company has analyzed the available information to determine the amount of the annual limitation. Based on information available to the Company, the limitation arising from this ownership change is estimated to range between $1.4 million and $3.7 million annually. In total, the Company estimates that the 2017 ownership change will result in approximately $102 million and $54 million of federal and state net operating loss carryforwards, respectively, expiring unused. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk

Concentration of Risk	6 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Concentration of Risk	3. Concentration of Risk Credit Risk Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. The Company maintains cash and money market funds with financial institutions that management deems reputable, and at times, cash balances may be in excess of Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insurance limits. The Company extends differing levels of credit to customers, and typically does not require collateral. The Company also maintains a cash balance at a bank in Switzerland, which is insured up to an amount specified by the deposit insurance agency of Switzerland. Customer Concentration During the three and six months ended June 30, 2017 and 2016, the following customers comprised more than 10% of revenues (unaudited ): Three Months June 30, 2017 Three Months June 30, 2016 Six Months June 30, 2017 Six Months June 30, 2016 Customer 1 14 % 0 % 9 % 0 % Customer 2 13 % 9 % 9 % 4 % Customer 3 12 % 9 % 12 % 4 % Customer 4 11 % 0 % 11 % 0 % Customer 5 10 % 0 % 7 % 0 % Customer 6 7 % 13 % 5 % 6 % Customer 7 0 % 17 % 0 % 9 % Customer 8 0 % 13 % 0 % 18 % Customer 9 0 % 13 % 0 % 6 % Customer 10 0 % 9 % 0 % 16 % As of June 30, 2017 and December 31, 2016, the following customers comprised more than 10% of accounts receivable: June 30, December 31, (unaudited) Customer 1 17 % 0 % Customer 2 17 % 0 % Customer 3 15 % 0 % Customer 4 15 % 0 % Customer 5 14 % 0 % Customer 6 11 % 0 % Customer 7 11 % 0 % Customer 8 0 % 34 % Customer 9 0 % 34 % Customer 10 0 % 29 % Geographic Concentration During the three and six months ended June 30, 2017 and 2016, regional revenue, based on customer locations which comprised more than 10% of revenues, consisted of the following (unaudited) : Three Months June 30, 2017 Three Months June 30, 2016 Six Months June 30, 2017 Six Months June 30, 2016 United States 50 % 61 % 52 % 48 % Taiwan 14 % 0 % 9 % 0 % Italy 11 % 29 % 11 % 27 % France 11 % 8 % 10 % 8 % Korea 10 % 0 % 7 % 0 % Sources of Supply Several of the components, materials and services used in the Company’s current Argus II product are available from only one supplier, and substitutes for these items cannot be obtained easily or would require substantial design or manufacturing modifications. Any significant problem experienced by one of the Company’s sole source suppliers could result in a delay or interruption in the supply of components to the Company until that supplier cures the problem or an alternative source of the component is located and qualified. Even where the Company could qualify alternative suppliers, the substitution of suppliers may be at a higher cost and create time delays that impede the commercial production of the Argus II and impact the Company’s abilities to deliver its products as may be timely required to meet demand. Foreign Operations The accompanying condensed consolidated financial statements as of June 30, 2017 (unaudited) and December 31, 2016 include assets amounting to $2.4 million and $1.7 million, respectively, relating to operations of the Company’s subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt the Company’s operations.

Money Market Funds

Money Market Funds	6 Months Ended
	Jun. 30, 2017
Cash and Cash Equivalents [Abstract]
Money Market Funds	4. Money Market Funds The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. Money market funds are the only financial instrument measured and recorded at fair value on the Company’s balance sheet, and they are considered Level 1 valuation securities. The following table presents money market funds at their level within the fair value hierarchy at June 30, 2017 and December 31, 2016 (in thousands): Total Level 1 Level 2 Level 3 June 30, 2017 (unaudited): Money market funds $ 17,366 $ 17,366 $ $ — December 31, 2016: Money market funds $ 10,336 $ 10,336 $ — $ —

Selected Balance Sheet Detail

Selected Balance Sheet Detail	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Detail	5. Selected Balance Sheet Detail Accounts receivable, net Accounts receivable consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Accounts receivable $ 1,108 $ 487 Allowance for doubtful accounts (182 ) (213 ) Accounts receivable, net $ 926 $ 274 Inventories, net Inventories consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Raw materials $ 401 $ 477 Work in process 4,045 5,032 Finished goods 2,527 3,284 6,973 8,793 Allowance for excess and obsolescence (3,921 ) (5,377 ) Inventories, net $ 3,052 $ 3,416 Property and equipment, net of accumulated depreciation and amortization Property and equipment consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Laboratory equipment $ 2,393 $ 2,300 Computer hardware and software 1,273 1,220 Leasehold improvements 299 288 Furniture, fixtures and equipment 46 45 4,011 3,853 Accumulated depreciation and amortization (2,597 ) (2,364 ) Property and equipment, net $ 1,414 $ 1,489

Equity Securities

Equity Securities	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Equity Securities	6. Equity Securities Common Stock Issuable Non-employee members of the Board of Directors are paid for their services in common stock on June 1 of each year based on the average closing prices for the immediately preceding twenty trading days. As of June 30, 2017, the Company accrued $21,000 for these services, which equates to 18,000 shares. These shares have not yet been issued and are excluded from the calculation of weighted average common shares outstanding for EPS purposes. Potentially Dilutive Common Stock Equivalents At June 30, 2017 and 2016, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands), as follows (unaudited): June 30, June 30, 2017 2016 Long Term Investor Rights — 343 Underwriter’s warrants 802 802 Warrants associated with convertible debt 1,038 1,038 Warrants associated with March 2017 Rights Offering 13,652 — Common stock options 5,536 3,588 Restricted stock units 107 190 Employee stock purchase plan 222 121 Total 21,357 6,082

Warrants

Warrants	6 Months Ended
	Jun. 30, 2017
Warrants
Warrants	7. Warrants A summary of warrant activity for the six months ended June 30, 2017 is presented below (in thousands, except per share and contractual life data) (unaudited). Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding at December 31, 2016 1,840 $ 7.72 1.80 Issued 13,652 $ 1.47 Exercised — Forfeited or expired — Warrants outstanding at June 30, 2017 15,492 $ 2.21 4.31 Warrants exercisable at June 30, 2017 15,492 $ 2.21 4.31 The intrinsic value of warrants outstanding at June 30, 2017 was $0.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation Effective June 1, 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”). On June 6, 2017, the shareholders approved amendments to the 2011 Plan increasing the maximum number of shares of common stock that may be issued from 7,500,000 to 9,500,000, which is offset and reduced by options previously granted under previous plans. The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the options vest ratably over either four or five years and expire ten years from the grant date. In the event of a change of control, as defined in the 2011 Plan, vesting is accelerated. A summary of stock option activity for the six months ended June 30, 2017 is presented below (in thousands, except per share and contractual life data) (unaudited) Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Options outstanding at December 31, 2016 3,667 $ 7.23 6.27 Granted 2,382 $ 1.88 Exercised — $ — Forfeited or expired (513 ) $ 5.68 Options outstanding at June 30, 2017 5,536 $ 5.07 7.67 Options exercisable at June 30, 2017 1,882 $ 6.93 5.12 The estimated aggregate intrinsic value of stock options exercisable at June 30, 2017 was $0. As of June 30, 2017, there was $6.5 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 3.0 years. During the six months ended June 30, 2017, the Company granted stock options to purchase 2,342,150 shares of common stock to certain employees. The options are exercisable for a period of ten years from the date of grant at prices ranging from $1.13 to $1.97 per share, which was the fair value of the Company’s common stock on the respective grant dates. The options vest over a period of four years. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $2,151,000 ($0.55 to $0.96 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.0%, a risk-free interest rate of 1.92% to 2.14%, and an expected dividend rate of 0%. In March 2017, the Company granted stock options to purchase 40,000 shares of common stock to an outside attorney in connection with his services relating to the Company’s March, 2017 rights offering to stockholders. The options are exercisable for a period of four years from the date of grant at a price of $1.76 per share, which was 120% of the fair value of the Company’s common stock on the grant date of March 6, 2017. The options vested as of the date of grant. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $19,640 ($0.49 per share). Assumptions used in the model were an expected term of 4.0 years, volatility of 48.0%, a risk-free interest rate of 1.81%, and an expected dividend rate of 0%. The cost of these shares was treated as an issuance cost of the offering and was deducted from the gross proceeds from the offering. The Company adopted an employee stock purchase plan (“ESPP”) starting in June 2015 for all eligible employees. On June 6, 2017, the shareholders approved an amendment to the ESPP increasing the maximum number of shares of common stock that may be issued from 250,000 to 750,000. Under the ESPP, shares of the Company’s common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period. At June 30, 2017, 435,139 shares had been purchased under the ESPP. The following table summarizes Restricted Stock Unit (RSU) activity (unaudited) for the six months ended June 30, 2017 (in thousands, except per share data): Number of Awards Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2016 131 $ 12.43 Awarded — — Vested (24 ) 12.43 Forfeited/canceled — — Outstanding as of June 30, 2017 107 $ 12.43 As of June 30, 2017, there was $1.3 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.1 years. Stock-based compensation expense recognized for stock-based awards granted under the 2011 Plan and the ESPP in the condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016 is as follows (in thousands ) (unaudited Three Months Ended June 30, 2017 Three Months Ended June 30, 2016 Six Months Ended June 30, 2017 Six Months Ended June 30, 2016 Cost of sales $ 67 $ 87 $ 148 $ 165 Research and development 75 83 132 160 Clinical and regulatory 44 45 93 93 Selling and marketing 112 (124 ) 206 (15 ) General and administrative 637 645 1,337 1,279 Total $ 935 $ 736 $ 1,916 $ 1,682

Litigation, Claims and Assessme

Litigation, Claims and Assessments	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Litigation, Claims and Assessments	9. Litigation, Claims and Assessments Eighteen oppositions have been filed by a third-party in the European Patent Office each challenging the validity of a European patent owned or exclusively licensed by the Company. The outcome of the challenges is not certain, however, if successful, they may affect the Company’s ability to block competitors from utilizing some of its patented technology in Europe. Management of the Company does not believe that a successful challenge will have a material effect on the Company’s ability to manufacture and sell its products, or otherwise have a material effect on the Company’s operations. The Company is party to litigation arising in the ordinary course of business. It is management’s opinion that the outcome of such matters will not have a material effect on the Company’s financial statements.

Basis of Presentation, Signif17

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2016 has been derived from the Company’s audited consolidated financial statements. In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2016.
Net Operating Loss Carryforward	Net Operating Loss Carryforward As of December 31, 2016 pursuant to an analysis done under Section 382, Limitations on Net Operating Losses, of the Internal Revenue Code of 1986, as amended, the Company had $142.3 million and $93.8 million of federal and state operating loss carryforwards, respectively, with which to offset any future taxable income. The federal and state net operating loss carryforwards will begin to expire at various dates from 2016 through 2036. If these loss carryforwards are unavailable for use in future periods, the Company’s results of operations and financial position may be adversely affected. The Company experienced an “ownership change” within the meaning of Section 382(g) of the Internal Revenue Code of 1986, as amended, during the second quarter of 2017. The ownership change will subject the Company’s net operating loss carryforwards to an annual limitation, which will significantly restrict the Company’s ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of the Company’s stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. The Company has analyzed the available information to determine the amount of the annual limitation. Based on information available to the Company, the limitation arising from this ownership change is estimated to range between $1.4 million and $3.7 million annually. In total, the Company estimates that the 2017 ownership change will result in approximately $102 million and $54 million of federal and state net operating loss carryforwards, respectively, expiring unused.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk (Tables)

Concentration of Risk (Tables)	6 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Schedule of revenues, accounts receivable & geographic concentration	During the three and six months ended June 30, 2017 and 2016, the following customers comprised more than 10% of revenues (unaudited): Three Months June 30, 2017 Three Months June 30, 2016 Six Months June 30, 2017 Six Months June 30, 2016 Customer 1 14 % 0 % 9 % 0 % Customer 2 13 % 9 % 9 % 4 % Customer 3 12 % 9 % 12 % 4 % Customer 4 11 % 0 % 11 % 0 % Customer 5 10 % 0 % 7 % 0 % Customer 6 7 % 13 % 5 % 6 % Customer 7 0 % 17 % 0 % 9 % Customer 8 0 % 13 % 0 % 18 % Customer 9 0 % 13 % 0 % 6 % Customer 10 0 % 9 % 0 % 16 % As of June 30, 2017 and December 31, 2016, the following customers comprised more than 10% of accounts receivable: June 30, December 31, (unaudited) Customer 1 17 % 0 % Customer 2 17 % 0 % Customer 3 15 % 0 % Customer 4 15 % 0 % Customer 5 14 % 0 % Customer 6 11 % 0 % Customer 7 11 % 0 % Customer 8 0 % 34 % Customer 9 0 % 34 % Customer 10 0 % 29 % Geographic Concentration During the three and six months ended June 30, 2017 and 2016, regional revenue, based on customer locations which comprised more than 10% of revenues, consisted of the following (unaudited) : Three Months June 30, 2017 Three Months June 30, 2016 Six Months June 30, 2017 Six Months June 30, 2016 United States 50 % 61 % 52 % 48 % Taiwan 14 % 0 % 9 % 0 % Italy 11 % 29 % 11 % 27 % France 11 % 8 % 10 % 8 % Korea 10 % 0 % 7 % 0 %

Money Market Funds (Tables)

Money Market Funds (Tables)	6 Months Ended
	Jun. 30, 2017
Cash and Cash Equivalents [Abstract]
Schedule of money market funds	The following table presents money market funds at their level within the fair value hierarchy at June 30, 2017 and December 31, 2016 (in thousands): Total Level 1 Level 2 Level 3 June 30, 2017 (unaudited): Money market funds $ 17,366 $ 17,366 $ $ — December 31, 2016: Money market funds $ 10,336 $ 10,336 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable	Accounts receivable consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Accounts receivable $ 1,108 $ 487 Allowance for doubtful accounts (182 ) (213 ) Accounts receivable, net $ 926 $ 274
Schedule of inventories	Inventories consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Raw materials $ 401 $ 477 Work in process 4,045 5,032 Finished goods 2,527 3,284 6,973 8,793 Allowance for excess and obsolescence (3,921 ) (5,377 ) Inventories, net $ 3,052 $ 3,416
Schedule of property and equipment	Property and equipment consisted of the following at (in thousands): June 30, December 31, 2017 2016 (Unaudited) Laboratory equipment $ 2,393 $ 2,300 Computer hardware and software 1,273 1,220 Leasehold improvements 299 288 Furniture, fixtures and equipment 46 45 4,011 3,853 Accumulated depreciation and amortization (2,597 ) (2,364 ) Property and equipment, net $ 1,414 $ 1,489

Equity Securities (Tables)

Equity Securities (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of anti-dilutive securities	At June 30, 2017 and 2016, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands), as follows (unaudited): June 30, June 30, 2017 2016 Long Term Investor Rights — 343 Underwriter’s warrants 802 802 Warrants associated with convertible debt 1,038 1,038 Warrants associated with March 2017 Rights Offering 13,652 — Common stock options 5,536 3,588 Restricted stock units 107 190 Employee stock purchase plan 222 121 Total 21,357 6,082

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2017
Warrants
Schedule of warrant activity	A summary of warrant activity for the six months ended June 30, 2017 is presented below (in thousands, except per share and contractual life data) (unaudited). Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding at December 31, 2016 1,840 $ 7.72 1.80 Issued 13,652 $ 1.47 Exercised — Forfeited or expired — Warrants outstanding at June 30, 2017 15,492 $ 2.21 4.31 Warrants exercisable at June 30, 2017 15,492 $ 2.21 4.31

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock option activity	A summary of stock option activity for the six months ended June 30, 2017 is presented below (in thousands, except per share and contractual life data) (unaudited). Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Options outstanding at December 31, 2016 3,667 $ 7.23 6.27 Granted 2,382 $ 1.88 Exercised — $ — Forfeited or expired (513 ) $ 5.68 Options outstanding at June 30, 2017 5,536 $ 5.07 7.67 Options exercisable at June 30, 2017 1,882 $ 6.93 5.12
Schedule of restricted stock unit (RSU) activity	The following table summarizes Restricted Stock Unit (RSU) activity (unaudited) for the six months ended June 30, 2017 (in thousands, except per share data): Number Weighted Outstanding as of December 31, 2016 131 $ 12.43 Awarded — — Vested (24 ) 12.43 Forfeited/canceled — — Outstanding as of June 30, 2017 107 $ 12.43
Schedule of stock-based compensation	Stock-based compensation expense recognized for stock-based awards granted under the 2011 Plan and the ESPP in the condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016 is as follows (in thousands) (unaudited): Three Months June 30, 2017 Three Months June 30, 2016 Six Months June 30, 2017 Six Months June 30, 2016 Cost of sales $ 67 $ 87 $ 148 $ 165 Research and development 75 83 132 160 Clinical and regulatory 44 45 93 93 Selling and marketing 112 (124 ) 206 (15 ) General and administrative 637 645 1,337 1,279 Total $ 935 $ 736 $ 1,916 $ 1,682

Organization and Business Ope24

Organization and Business Operations (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 06, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2007
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price (in dollars per share)		$ 2.21	$ 7.72
Right Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of units	$ 19,700
Number of units sold	13,700
Unit price (in dollars per unit)	$ 1.47
Description of unit	Each Unit consisted of a share of the Company’s common stock and a warrant to purchase an additional share of the Company’s stock for $1.47.
Relative fair value of common stock (in dollars per share)	$ 1.02
Right Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Share price (in dollars per share)	1.47
Warrant exercise price (in dollars per share)	0.64
Relative fair value of warrants (in dollars per share)	$ 0.45
Warrant term	5 years
Second Sight (Switzerland) Sarl [Member]
Subsidiary, Sale of Stock [Line Items]
Ownership percentage by parent		100.00%		99.50%
Second Sight (Switzerland) Sarl [Member] | Executive Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Ownership percentage by noncontrolling interest				0.50%

Basis of Presentation, Signif25

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Net operating loss carryforwards limitations	The Company has analyzed the available information to determine the amount of the annual limitation. Based on information available to the Company, the limitation arising from this ownership change is estimated to range between $1.4 million and $3.7 million annually. In total, the Company estimates that the 2017 ownership change will result in approximately $102 million and $54 million of federal and state net operating loss carryforwards, respectively, expiring unused.
Federal [Member]
Net operating loss carryforwards		$ 142,300
State [Member]
Net operating loss carryforwards		$ 93,800

Concentration of Risk (Details)

Concentration of Risk (Details) - Sales Revenue, Net [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Customer 1 [Member]
Customer Concentration	14.00%	0.00%	9.00%	0.00%
Customer 2 [Member]
Customer Concentration	13.00%	9.00%	9.00%	4.00%
Customer 3 [Member]
Customer Concentration	12.00%	9.00%	12.00%	4.00%
Customer 4 [Member]
Customer Concentration	11.00%	0.00%	11.00%	0.00%
Customer 5 [Member]
Customer Concentration	10.00%	0.00%	7.00%	0.00%
Customer 6 [Member]
Customer Concentration	7.00%	13.00%	5.00%	6.00%
Customer 7 [Member]
Customer Concentration	0.00%	17.00%	0.00%	9.00%
Customer 8 [Member]
Customer Concentration	0.00%	13.00%	0.00%	18.00%
Customer 9 [Member]
Customer Concentration	0.00%	13.00%	0.00%	6.00%
Customer 10 [Member]
Customer Concentration	0.00%	9.00%	0.00%	16.00%

Concentration of Risk (Details

Concentration of Risk (Details 1) - Accounts Receivable [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Customer 1 [Member]
Customer Concentration	17.00%	0.00%
Customer 2 [Member]
Customer Concentration	17.00%	0.00%
Customer 3 [Member]
Customer Concentration	15.00%	0.00%
Customer 4 [Member]
Customer Concentration	15.00%	0.00%
Customer 5 [Member]
Customer Concentration	14.00%	0.00%
Customer 6 [Member]
Customer Concentration	11.00%	0.00%
Customer 7 [Member]
Customer Concentration	11.00%	0.00%
Customer 8 [Member]
Customer Concentration	0.00%	34.00%
Customer 9 [Member]
Customer Concentration	0.00%	34.00%
Customer 10 [Member]
Customer Concentration	0.00%	29.00%

Concentration of Risk (Detail28

Concentration of Risk (Details 2)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
UNITED STATES
Customer Concentration	50.00%	61.00%	52.00%	48.00%
TAIWAN
Customer Concentration	14.00%	0.00%	9.00%	0.00%
ITALY
Customer Concentration	11.00%	29.00%	11.00%	27.00%
FRANCE
Customer Concentration	11.00%	8.00%	10.00%	8.00%
KOREA
Customer Concentration	10.00%	0.00%	7.00%	0.00%

Concentration of Risk (Detail29

Concentration of Risk (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets	$ 24,267	$ 16,810
Second Sight (Switzerland) Sarl [Member]
Assets	$ 2,400	$ 1,700

Money Market Funds (Details)

Money Market Funds (Details) - Money Market Funds [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Money market funds	$ 17,366	$ 10,336
Level 1 [Member]
Money market funds	17,366	10,336
Level 2 [Member]
Money market funds
Level 3 [Member]
Money market funds

Selected Balance Sheet Detail31

Selected Balance Sheet Detail (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Selected Balance Sheet Detail Details
Accounts receivable	$ 1,108	$ 487
Allowance for doubtful accounts	(182)	(213)
Accounts receivable, net	$ 926	$ 274

Selected Balance Sheet Detail32

Selected Balance Sheet Detail (Details 1) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 401	$ 477
Work in process	4,045	5,032
Finished goods	2,527	3,284
Inventories, gross	6,973	8,793
Allowance for excess and obsolescence	(3,921)	(5,377)
Inventories, net	$ 3,052	$ 3,416

Selected Balance Sheet Detail33

Selected Balance Sheet Detail (Details 2) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,011	$ 3,853
Accumulated depreciation and amortization	(2,597)	(2,364)
Property and equipment, net	1,414	1,489
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,393	2,300
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,273	1,220
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	299	288
Furniture, Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 46	$ 45

Equity Securities (Details)

Equity Securities (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Total anti-dilutive securities	21,357	6,082
Long Term Investor Rights [Member]
Total anti-dilutive securities		343
Underwriter's Warrants [Member]
Total anti-dilutive securities	802	802
Warrants Associated With Convertible Debt [Member]
Total anti-dilutive securities	1,038	1,038
Warrants Associated With Rights Offering [Member]
Total anti-dilutive securities	13,652
Common Stock Options [Member]
Total anti-dilutive securities	5,536	3,588
Restricted Stock Units [Member]
Total anti-dilutive securities	107	190
Employee Stock Purchase Plan [Member]
Total anti-dilutive securities	222	121

Equity Securities (Details Narr

Equity Securities (Details Narrative) - Non-Employee [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)shares
Accrued services | $	$ 21
Number of shares issued for services | shares	18

Warrants (Details)

Warrants (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Class Of Warrant Or Right Number Of Shares [Roll Forward]
Warrants outstanding at beginning | shares	1,840
Issued | shares	13,652
Warrants outstanding at end | shares	15,492
Warrants exercisable at end | shares	15,492
Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]
Warrants outstanding at beginning | $ / shares	$ 7.72
Issued | $ / shares	1.47
Warrants outstanding at end | $ / shares	2.21
Warrants exercisable at end | $ / shares	$ 2.21
Class Of Warrant Or Right Weighted Average Remaining Contractual Life [Roll Forward]
Warrants outstanding at beginning	1 year 9 months 18 days
Warrants outstanding at end	4 years 3 months 22 days
Warrants exercisable at end	4 years 3 months 22 days

Warrants (Details Narrative)

Warrants (Details Narrative) $ in Thousands	Jun. 30, 2017USD ($)
Warrants [Member]
Intrinsic value of warrants outstanding	$ 0

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning | shares	3,667
Granted | shares	2,382
Exercised | shares
Forfeited or expired | shares	(513)
Options outstanding at ending | shares	5,536
Options exercisable at ending | shares	1,882
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Options outstanding at beginning | $ / shares	$ 7.23
Granted | $ / shares	1.88
Exercised | $ / shares
Forfeited or expired | $ / shares	5.68
Options outstanding at ending | $ / shares	5.07
Options exercisable at ending | $ / shares	$ 6.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Life [Roll Forward]
Options outstanding at beginning	6 years 3 months 7 days
Options outstanding at ending	7 years 8 months 1 day
Options exercisable at ending	5 years 1 month 13 days

Stock-Based Compensation (Det39

Stock-Based Compensation (Details 1) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Outstanding at beginning | shares	131
Awarded | shares
Vested | shares	(24)
Forfeited/canceled | shares
Outstanding at ending | shares	107
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]
Outstanding at beginning | $ / shares	$ 12.43
Awarded | $ / shares
Vested | $ / shares	12.43
Forfeited/canceled | $ / shares
Outstanding at ending | $ / shares	$ 12.43

Stock-Based Compensation (Det40

Stock-Based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total	$ 935	$ 736	$ 1,916	$ 1,682
Cost of Sales [Member]
Total	67	87	148	165
Research and Development [Member]
Total	75	83	132	160
Clinical And Regulatory [Member]
Total	44	45	93	93
Selling and Marketing [Member]
Total	112	(124)	206	(15)
General and Administrative [Member]
Total	$ 637	$ 645	$ 1,337	$ 1,279

Stock-Based Compensation (Det41

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 06, 2017	Jun. 30, 2015	Mar. 31, 2017	Jun. 30, 2017
Number of shares exercised
Exercise price (in dollars per share)
Number of options granted				2,382
Restricted Stock Units [Member]
Period of recognized compensation cost				2 years 1 month 6 days
Total non vested unrecognized compensation cost				$ 1,300
Certain Employees [Member]
Number of options granted				2,342,150
Exercisable terms				10 years
Vesting period				4 years
Fair value of options				$ 2,151
Expected terms				6 years 3 months
Volatility rate				48.00%
Expected dividend rate				0.00%
Outside Attorney [Member]
Exercise price (in dollars per share)			$ 1.76
Share price (in dollars per share)			$ 0.49
Number of options granted			40,000
Exercisable terms			4 years
Fair value of options			$ 19,640
Expected terms			4 years
Volatility rate			48.00%
Risk-free interest rate			1.81%
Expected dividend rate			0.00%
Minimum [Member] | Certain Employees [Member]
Exercise price (in dollars per share)				$ 1.13
Share price (in dollars per share)				$ 0.55
Risk-free interest rate				1.92%
Maximum [Member] | Certain Employees [Member]
Exercise price (in dollars per share)				$ 1.97
Share price (in dollars per share)				$ 0.96
Risk-free interest rate				2.14%
2011 Equity Incentive Plan [Member]
Aggregate exercisable intrinsic value				$ 0
Total unrecognized compensation cost of options				$ 6,500
Period of recognized compensation cost				3 years
Exercisable terms				10 years
Previously issued number of shares	7,500,000
Number of shares issued	9,500,000
2011 Equity Incentive Plan [Member] | Minimum [Member]
Vesting period				4 years
2011 Equity Incentive Plan [Member] | Maximum [Member]
Vesting period				5 years
2015 Employee Stock Purchase Plan [Member]
Previously issued number of shares	250,000
Number of shares issued	750,000
Employee Stock Purchase Plan [Member]
Description of plan		Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period.
Number of shares issued				435,139